Hiroyuki Okuzawa Representative Director, President & COO Koji Ogawa Executive Officer, Head of Global Corporate Planning & Management, CFO Ken Takeshita Head of R&D Unit Wataru Takasak Executive Officer, Head of R&D Division PLAY LIST from the beginning FY2023 Q2 Financial Results Presentation Forward-Looking Statements 1.FY2023 Q2 Financial Results Overview of FY2023 Q2 Results Revenue Core Operating Profit Profit Attributable to Owners of the Company Revenue: Business Units (incl. Forex Impact) Revenue: Major Products in Japan 2.Strategic Collaboration Overview of Strategic Collaboration Financial Terms for Strategic Collaboration How R&D Expenses will be Shared, and How Cash will be Paid 3.FY2023 Forecast/ Annual Dividend Revision to the forecast Revision of Annual Dividend 4.Business Update Revenue Performance in Each Region (US, EU) Performance in Each Region (Japan, ASCA) LIXIANA : Growth in Each Country/Region LIXIANA : Growth in Japan Major Update on Patent Disputes 5.R&D Update 5DXd-ADCs Update Two Breakthrough Therapy Designations DESTINY-PanTumor02 Additional updates in clinical studies and regulatory communications TROPION-Lung01 overall efficacy in NSCLC 2/3L TROPION-Lung01 efficacy in non-sq and sq NSCLC TROPION-Lung01 Safety TROPION-Lung05 TROPION-Lung04 TROPION-Breast01 BEGONIA Data Update HERTHENA-Lung01 study Ph1/2 Study Data Update Ph1 Study OVC Cohort Data Update External reputations to DXd-ADC technology Next Wave Update Development status of COVID-19 vaccine Clinical and Regulatory Progress R&D day R&D Day 2023 News Flow FY2023 News Flow 6.Appendix Major R&D Milestones (5DXd-ADCs (1)) Major R&D Milestones (5DXd-ADCs (2)) Major R&D Milestones (Next Wave) Major R&D Pipeline: 5DXd-ADCs Major R&D Pipeline: Next Wave @ Q&A Q&A 1 Q&A 2 Q&A 3 Q&A 4 Q&A 5 Q&A 6 Q&A 7 Q&A 8 Back Next